UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~June 18, 2024

PRESSURE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Massachusetts	001-38185	04-2652826
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

480 Neponset St.

Canton, MA 02021

(Address of Principal Executive Office) (Zip Code)

(508) 230-1828

(Registrant’s telephone number, including area code)

14 Norfolk Avenue

South Easton, MA 02375

(Former Address of Principal Executive Office)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.0702. ~~Submission~~Departure of ~~Matters~~Directors toor aCertain ~~Vote~~Officers; Election of ~~Security~~Directors; ~~Holders~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~April~~June 18, 2024, ~~Pressure~~Kevin ~~BioSciences, Inc~~A. ~~(the~~Pollack, ~~“Company”) held~~ a ~~special~~member ~~meeting in lieu~~ of the ~~annual~~Board ~~meeting~~ of ~~stockholders~~ Directors (the “~~Meeting~~Board”). Atof ~~the~~Pressure ~~Meeting~~BioSciences, ~~the~~Inc. ~~stockholders voted on~~ (the ~~following proposals described in detail in the~~ “Company’s”), ~~definitive~~resigned, ~~proxy~~effective ~~statement~~immediately. ~~for~~Additionally, ~~the Meeting filed with the Securities and Exchange Commission~~ on ~~February~~June 2718, 2024~~. As of the record date for the Meeting~~, ~~there~~Vito ~~were~~J. 28Mangiardi,~~372,923~~ ~~shares~~a ofmember of the ~~Company’s~~Board, ~~common stock~~resigned, ~~par~~effective ~~value $0~~immediately.01 ~~per~~Their ~~share,~~resignations ~~issued~~did ~~and~~not ~~outstanding and~~express ~~entitled~~disagreements towith ~~one vote for each share held. The holders of 54.71% of~~ the Company’s, ~~shares~~and ofboth ~~common~~resigning ~~stock outstanding (15,523,934)~~Board ~~submitted~~members ~~votes~~affirmed bytheir ~~proxy~~wishes orfor inthe ~~person~~future atsuccess of the ~~Meeting,~~ ~~constituting a quorum~~Company.

~~Proposal~~On 1behalf -of ~~Elect~~the ~~one~~Company, ~~director~~Board asChairman aJeffrey ~~Class~~N. ~~III~~Peterson ~~Director~~and ~~until~~CEO ~~the~~Richard ~~2026~~T. ~~Annual~~Schumacher ~~Meeting~~express their deep appreciation for the 12 years of ~~Stockholders~~Board service received from Messrs. Pollack and Mangiardi. The ~~election~~Board ofdoes ~~the~~not intend to fill these director ~~was~~vacancies ~~approved as~~at ~~follows:~~this time.

Nominee		For				Against				Shares voted Withhold				Broker Non-Votes
Richard T. Schumacher			7,109,810				1,638,664				533,157				6,242,303

Proposal 2 - Ratify the appointment of MaloneBailey LLP as the Company’s independent auditor for fiscal year 2023. The ratification of the appointment of MaloneBailey LLP as the Company’s independent auditor for fiscal year 2023 was approved as follows:

	Shares voted
For		13,900,704
Against		787,086
Abstain		836,144
Broker Non-Votes		0

Proposal 3 – Approve the Pressure BioSciences, Inc. 2024 Equity Incentive Plan. The Pressure BioSciences, Inc. 2024 Equity Incentive Plan was approved as follows:

	Shares voted
For		6,474,213
Against		2,696,003
Abstain		111,415
Broker Non-Votes		6,242,303

Proposal 4 – Approval, on an advisory basis, of a non-binding resolution to approve the compensation of our named executive officers. The non-binding resolution was approved as follows:

	Shares voted
For		5,961,481
Against		2,337,936
Abstain		982,214
Broker Non-Votes		6,242,303

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	PRESSURE BIOSCIENCES, INC.
Dated: April 22, 2024	By:	/s/ Richard T. Schumacher
Dated: July 3, 2024	By:	/s/ Richard T. Schumacher
		Richard T. Schumacher President and Chief Executive Officer
		Richard T. Schumacher
		President and Chief Executive Officer

Filing Compare · PRESSURE BIOSCIENCES INC